留给绽妍生物的时间不多了

Core Viewpoint - The skincare brand Zhenyan Bio, which is preparing for an IPO on the Beijing Stock Exchange, has not kept pace with industry expansion despite its early entry into the market. The company has struggled to transition from a hospital-backed brand to a mainstream consumer brand, resulting in a significant gap in market presence and financial performance compared to leading competitors [1][9]. Financial Performance - Zhenyan Bio's revenue is projected to grow from 486 million yuan to 597 million yuan from 2023 to 2024, representing a year-on-year increase of approximately 22.8%. However, its net profit is expected to grow by only 7%, reaching 73 million yuan [2]. - In contrast, leading companies like Winona and Juzibio have already surpassed the 1 billion yuan revenue mark, indicating a structural gap in financial scale [2]. Market Share - Zhenyan Bio's market share in the skin barrier repair medical dressing market has remained below 4% from 2021 to 2023, failing to capitalize on the market's increasing fragmentation and heightened competition [2]. - While competitors like Juzibio and Fuyoujia have seen their market shares decline, Zhenyan Bio has not gained any significant market share during this period [2]. Channel Strategy - The company's sales system still reflects characteristics of an "in-hospital brand," with a high reliance on offline channels, including hospitals and OTC pharmacies, which accounted for 58.91% of total revenue in the past year [7]. - Zhenyan Bio has begun to adjust its channel structure, with the proportion of revenue from distribution decreasing to 44.88% as it shifts towards online direct sales and consignment [7]. Brand Positioning - Zhenyan Bio has launched sub-brands like "Zhenxiaoyan" for infant skincare and "Defilin" for bioactive compounds, but these attempts are still in the early stages and lack significant market presence [8]. - The company has not established a clear differentiation in product functionality, pricing, and brand positioning compared to competitors, limiting its ability to gain market traction [4][8]. Future Outlook - The company's challenges stem from its failure to upgrade its business model at critical stages, missing opportunities for channel transformation and brand amplification [9]. - The decision to pursue an IPO is seen as a strategy to secure time and resources for future transformation, although the window for catching up with competitors is narrowing [9].